Patidegib Topical Gel, 2%
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Basal Cell Nevus Syndrome
Conditions
Basal Cell Nevus Syndrome
Trial Timeline
Jun 3, 2020 → Jul 14, 2021
NCT ID
NCT04308395About Patidegib Topical Gel, 2%
Patidegib Topical Gel, 2% is a phase 3 stage product being developed by Sol-Gel Technologies for Basal Cell Nevus Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT04308395. Target conditions include Basal Cell Nevus Syndrome.
What happened to similar drugs?
1 of 6 similar drugs in Basal Cell Nevus Syndrome were approved
Approved (1) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
17
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04308395 | Phase 3 | Terminated |
| NCT04155190 | Phase 2 | Terminated |
| NCT03703310 | Phase 3 | Completed |
Competing Products
20 competing products in Basal Cell Nevus Syndrome